Summary
ZURICH/LONDON (Reuters) - Hedge fund shareholdercalled for Actelion to explore a possible sale, and for the Swiss biotech's chairman and chief executive to resign from the board.
Shares in Actelion rose more than 4 percent after it emerged Elliott had sent a letter, which said Chief Executive Jean-Paul Clozel's attitude to a potential sale of the company, worth around 6.7 billion Swiss francs ($7.10 billion), was not in shareholders' interests.See the full content of this document
Extract
Hedge Fund Urges Actelion Board Shake-Up
"We believe his public statements and apparent campaign to keep the company independent are wholly inconsistent with his position as a board member and the fiduciary requirements of that ...
See the full content of this document
Sponsored links
